CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis
USA - NASDAQ:CSBR - US15870P3073 - Common Stock
6.487 USD
-0.07 (-1.11%)
Overall CSBR gets a fundamental rating of 5 out of 10. We evaluated CSBR against 56 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of CSBR while its profitability can be described as average. CSBR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CSBR was profitable.
In the past year CSBR had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CSBR reported negative net income in multiple years.
In multiple years CSBR reported negative operating cash flow during the last 5 years.
1.2 Ratios
CSBR has a better Return On Assets (9.66%) than 87.50% of its industry peers.
CSBR has a Return On Equity of 84.15%. This is amongst the best in the industry. CSBR outperforms 98.21% of its industry peers.
Looking at the Return On Invested Capital, with a value of 30.30%, CSBR belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| ROIC | 30.3% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 5.19%, CSBR is doing good in the industry, outperforming 67.86% of the companies in the same industry.
CSBR's Profit Margin has improved in the last couple of years.
CSBR has a better Operating Margin (5.29%) than 60.71% of its industry peers.
In the last couple of years the Operating Margin of CSBR has grown nicely.
CSBR has a Gross Margin (48.47%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CSBR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.29% | ||
| PM (TTM) | 5.19% | ||
| GM | 48.47% |
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
2. Health
2.1 Basic Checks
CSBR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CSBR has more shares outstanding than it did 1 year ago.
CSBR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CSBR has a worse debt to assets ratio.
2.2 Solvency
CSBR has an Altman-Z score of 0.45. This is a bad value and indicates that CSBR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.45, CSBR is doing worse than 71.43% of the companies in the same industry.
The Debt to FCF ratio of CSBR is 0.03, which is an excellent value as it means it would take CSBR, only 0.03 years of fcf income to pay off all of its debts.
CSBR has a Debt to FCF ratio of 0.03. This is amongst the best in the industry. CSBR outperforms 92.86% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that CSBR is not too dependend on debt financing.
The Debt to Equity ratio of CSBR (0.02) is better than 66.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 0.45 |
ROIC/WACC2.91
WACC10.42%
2.3 Liquidity
CSBR has a Current Ratio of 0.93. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CSBR (0.93) is worse than 91.07% of its industry peers.
A Quick Ratio of 0.93 indicates that CSBR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.93, CSBR is doing worse than 83.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 |
3. Growth
3.1 Past
CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 289.47%, which is quite impressive.
The Earnings Per Share has been growing by 146.62% on average over the past years. This is a very strong growth
Looking at the last year, CSBR shows a quite strong growth in Revenue. The Revenue has grown by 10.11% in the last year.
The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)289.47%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-81.82%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.47%
3.2 Future
Based on estimates for the next years, CSBR will show a very negative growth in Earnings Per Share. The EPS will decrease by -41.69% on average per year.
Based on estimates for the next years, CSBR will show a quite strong growth in Revenue. The Revenue will grow by 18.26% on average per year.
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CSBR is valuated rather expensively with a Price/Earnings ratio of 18.02.
Based on the Price/Earnings ratio, CSBR is valued cheaper than 87.50% of the companies in the same industry.
When comparing the Price/Earnings ratio of CSBR to the average of the S&P500 Index (27.40), we can say CSBR is valued slightly cheaper.
CSBR is valuated quite expensively with a Price/Forward Earnings ratio of 42.40.
CSBR's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.94. CSBR is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.02 | ||
| Fwd PE | 42.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSBR is valued cheaply inside the industry as 80.36% of the companies are valued more expensively.
96.43% of the companies in the same industry are more expensive than CSBR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.42 | ||
| EV/EBITDA | 17.62 |
4.3 Compensation for Growth
The decent profitability rating of CSBR may justify a higher PE ratio.
CSBR's earnings are expected to decrease with -41.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.69%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CSBR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CSBR (10/17/2025, 4:04:02 PM)
6.487
-0.07 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners48.17%
Inst Owner Change0%
Ins Owners26.06%
Ins Owner Change0%
Market Cap89.46M
Analysts82.86
Price Target12.24 (88.69%)
Short Float %0.9%
Short Ratio2.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)180.88%
Min EPS beat(2)65.69%
Max EPS beat(2)296.08%
EPS beat(4)4
Avg EPS beat(4)1095.34%
Min EPS beat(4)65.69%
Max EPS beat(4)3629.41%
EPS beat(8)7
Avg EPS beat(8)599.88%
EPS beat(12)8
Avg EPS beat(12)365.32%
EPS beat(16)10
Avg EPS beat(16)266.15%
Revenue beat(2)2
Avg Revenue beat(2)1.19%
Min Revenue beat(2)0.83%
Max Revenue beat(2)1.54%
Revenue beat(4)4
Avg Revenue beat(4)8.21%
Min Revenue beat(4)0.83%
Max Revenue beat(4)29.17%
Revenue beat(8)6
Avg Revenue beat(8)2.62%
Revenue beat(12)7
Avg Revenue beat(12)0.98%
Revenue beat(16)10
Avg Revenue beat(16)1.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-87.5%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.56%
Revenue NY rev (1m)-1.82%
Revenue NY rev (3m)-1.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.02 | ||
| Fwd PE | 42.4 | ||
| P/S | 1.57 | ||
| P/FCF | 12.42 | ||
| P/OCF | 11.72 | ||
| P/B | 25.5 | ||
| P/tB | 28.19 | ||
| EV/EBITDA | 17.62 |
EPS(TTM)0.36
EY5.55%
EPS(NY)0.15
Fwd EY2.36%
FCF(TTM)0.52
FCFY8.05%
OCF(TTM)0.55
OCFY8.53%
SpS4.12
BVpS0.25
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| ROCE | 38.35% | ||
| ROIC | 30.3% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 5.29% | ||
| PM (TTM) | 5.19% | ||
| GM | 48.47% | ||
| FCFM | 12.66% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score7
Asset Turnover1.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 28.08% | ||
| Cap/Sales | 0.76% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 167.47% | ||
| Profit Quality | 243.9% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 | ||
| Altman-Z | 0.45 |
F-Score7
WACC10.42%
ROIC/WACC2.91
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)289.47%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-81.82%
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.11%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.47%
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y199.05%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-7.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y375.86%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y4141.67%
OCF growth 3Y4.35%
OCF growth 5Y20.48%